IFM launches subsidiary with $31M series A

IFM Therapeutics LLC (Boston, Mass.) launched inflammatory disease-focused subsidiary IFM Tre Inc. with a $31 million series A round co-led by Atlas Venture, Abingworth, Bristol-Myers Squibb Co. (NYSE:BMY) and IFM’s management.

IFM Tre

Read the full 329 word article

User Sign In